Efficacy outcomes and safety measures
death, SD
DISEASE, TUMOR PROGRESSION, ADVERSE EVENT, DISEASE, COMPLICATIONS
The primary study endpoint was PFS, according to RECIST version 1.1, which is defined as the time from enrollment until objective tumor progression or death. OS is defined as the time from patient enrolment to the time of death from any cause. The partial response (PR) is defined as at least a 30% decrease in the sum of the target lesions. Stable disease (SD) is defined as fitting the criteria neither for progressive disease nor a PR. Objective response rate (ORR) is the percentage of patients with partial response and/or complete response. Disease control rate (DCR) is the percentage of patients achieved complete response, partial response, and stable disease. Patient characteristics (age, sex, lesions, treatment lines, and the number of ATRA/apatinib cycles) and treatment outcomes (best response, PFS, complications, AE and follow‐up) were extracted from the medical charts and telephone follow‐up. Safety evaluations at all study visits included laboratory and adverse event (AE) assessments adhering to NCI Common Terminology Criteria version 4.0. The patients were evaluated every two cycles. The last follow‐up time was in October 2021.